medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2019-2-26(401)-44-48medalphabet-1146Research ArticleВ ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУРанняя диагностика псориатического артрита и возможности контроля над заболеванием (обзор литературы)Early diagnosis of psoriatic arthritis and possibility of its control (literature review)КругловаЛ. С.KruglovaL. S.

проректор по учебной работе, зав. кафедрой дерматовенерологии и косметологии 

г. Москва

Moscow

ЛьвовА. Н.LvovA. N.

д. м. н., проф., рук. отдела клинической дерматовенерологии и косметологии

г. Москва

Moscow

ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РоссииРоссияCentral State Medical Academy of the Administrative Department of the President of RussiaRussian FederationГБУЗ г. Москвы «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. МосквыРоссияMoscow Scientific and Practical Centre for Dermatovenereology and CosmetologyRussian Federation201919112019226Дерматология4448Copyright © Круглова Л.С., Львов А.Н., 20192019Круглова Л.С., Львов А.Н.Kruglova L.S., Lvov A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1146

Статья носит обзорный характер и содержит современные данные о факторах рисках развития псориатического артрита у пациентов с псориазом. Приведены данные о диагностике, клинической картине ПсА и целесообразности раннего назначения генно-инженерных препаратов с целью повышения эффективности и улучшения прогноза заболевания.

The article is of an overview nature and contains current data on risk factors for the development of psoriatic arthritis in patients with psoriasis. The data on the diagnosis, clinical picture of PsA and the feasibility of the early appointment of biologics medicines in order to increase efficiency and improve the prognosis of the disease are given.

ИЛ-17сигнальный путьпсориазпсориатический артритсекукинумабраннее назначение генно-инженерных препаратовIL-17signaling pathwaypsoriasispsoriatic arthritissecukinumabearly prescription of biologic therapyReferencesCoates L. C., Kavanaugh A., Mease P. J., et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015. Arthritis Rheumatol. 2016 May; 68 (5): 1060–71.Coates L. C., Kavanaugh A., Mease P. J., et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015. Arthritis Rheumatol. 2016 May; 68 (5): 1060–71.Olivieri I., Padula A., D’Angelo S., et al. Psoriatic arthritis sine psoriasis. J Rheumatol Suppl. 2009; 83: 28–9.Olivieri I., Padula A., D’Angelo S., et al. Psoriatic arthritis sine psoriasis. J Rheumatol Suppl. 2009; 83: 28–9.Carneiro C., Chaves M., Verardino G., et al. Evaluation off atigueandits correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. Clin. Cosmet. Investig. Dermatol. 2017, 10, 155–163.Carneiro C., Chaves M., Verardino G., et al. Evaluation off atigueandits correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. Clin. Cosmet. Investig. Dermatol. 2017, 10, 155–163.Haddad A., Zisman D. Comorbidities in Patients with Psoriatic Arthritis. Rambam Maimonides Med. J. 2017, 8, e0004.Haddad A., Zisman D. Comorbidities in Patients with Psoriatic Arthritis. Rambam Maimonides Med. J. 2017, 8, e0004.Augustin M., Vietri J., Tian H., Gilloteau I. Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 1316–1323.Augustin M., Vietri J., Tian H., Gilloteau I. Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 1316–1323.Boutet M. A., Nerviani A., Gallo Afflitto G., Pitzalis C. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018; 19(2): 530.Boutet M. A., Nerviani A., Gallo Afflitto G., Pitzalis C. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018; 19(2): 530.Di Cesare A., Di Meglio P., Nestle F. O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009 Jun; 129 (6): 1339–50.Di Cesare A., Di Meglio P., Nestle F. O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009 Jun; 129 (6): 1339–50.Acosta Felquer M., FitzGerald О. Peripheral joint involvement in psoriatic arthritis patients. Clin Exp Rheumatol. 2015 Sep-Oct; 33 (5 Suppl 93): S 26–30.Acosta Felquer M., FitzGerald О. Peripheral joint involvement in psoriatic arthritis patients. Clin Exp Rheumatol. 2015 Sep-Oct; 33 (5 Suppl 93): S 26–30.Коротаева Т. В. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2014; 52 (6): 650–659.Коротаева Т. В. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2014; 52 (6): 650–659.Gladman D. D., Ziouzina O., Thavaneswaran A., Chandran V. J. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. Rheumatol. 2013 Aug; 40 (8): 1357–9.Gladman D. D., Ziouzina O., Thavaneswaran A., Chandran V. J. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. Rheumatol. 2013 Aug; 40 (8): 1357–9.Sakkas L. I., Alexiou I., Simopoulou T., Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013 Dec; 43 (3): 325–34.Sakkas L. I., Alexiou I., Simopoulou T., Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013 Dec; 43 (3): 325–34.McGonagle D.G., Helliwell P., Veale D. Enthesitis in psoriatic disease. Dermatology. 2012; 225 (2): 100–9.McGonagle D.G., Helliwell P., Veale D. Enthesitis in psoriatic disease. Dermatology. 2012; 225 (2): 100–9.Celis R., Cuervo A., Ramírez J., Cañete JD. Psoriatic Synovitis: Singularity and Potential Clinical Implications. Front Med (Lausanne). 2019; 6: 14. Published 2019 Feb 11.Celis R., Cuervo A., Ramírez J., Cañete JD. Psoriatic Synovitis: Singularity and Potential Clinical Implications. Front Med (Lausanne). 2019; 6: 14. Published 2019 Feb 11.Ash Z., Tinazzi I., Gallego C., et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis. 2012 Apr; 71 (4): 553–556.Ash Z., Tinazzi I., Gallego C., et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis. 2012 Apr; 71 (4): 553–556.Wilson F. C. et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a populationbased study. Arthritis Rheum. — 2009. — 61, 233–239.Wilson F. C. et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a populationbased study. Arthritis Rheum. — 2009. — 61, 233–239.Nedoszytko B., Sokołowska-Wojdyło M., Ruckemann-Dziurdzin´ska K., Roszkiewicz J., Nowicki R. J. Chemokines and cytokines networkin the pathogenesis of the inflammatory skin diseases: Atopicdermatitis, psoriasis and skin mastocytosis. Adv. Dermatol. Allergol. 2014, 2, 84–91.Nedoszytko B., Sokołowska-Wojdyło M., Ruckemann-Dziurdzin´ska K., Roszkiewicz J., Nowicki R. J. Chemokines and cytokines networkin the pathogenesis of the inflammatory skin diseases: Atopicdermatitis, psoriasis and skin mastocytosis. Adv. Dermatol. Allergol. 2014, 2, 84–91.Gladman D. D. Recent advances in understanding and managing psoriatic arthritis. F1000 Research 2016, 5, 2670.Gladman D. D. Recent advances in understanding and managing psoriatic arthritis. F1000 Research 2016, 5, 2670.Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthr. Rheum. 2006; 54 (8): 2665–73.Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthr. Rheum. 2006; 54 (8): 2665–73.Coates L., Helliwell P. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthr. Care Res. 2010; 62 (7): 965–9.Coates L., Helliwell P. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthr. Care Res. 2010; 62 (7): 965–9.Rouzaud M., Sevrain M., Villani A. P., et al. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 17–26.Rouzaud M., Sevrain M., Villani A. P., et al. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 17–26.Haroon M., Kirby B., FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013; 72: 736–740.Haroon M., Kirby B., FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013; 72: 736–740.Coates LC., Aslam T., Al Balushi F., et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol. 2013; 168: 802–807.Coates LC., Aslam T., Al Balushi F., et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol. 2013; 168: 802–807.Mease PJ., Gladman DD., Helliwell P., et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2014; 71: 649–655.Mease PJ., Gladman DD., Helliwell P., et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2014; 71: 649–655.Чамурлиева М. Н., Логинова Е. Ю., Коротаева Т. В., Баткаев Э. А. Поражение костно-суставного аппарата у больных псориазом по данным скринингового опросника PEST (Psoriasis Epydemiology Screening Tool) и ревматологического клинико-инструментального обследования. Научно-практическая ревматология. 2014; 52 (6): 636–642.Чамурлиева М. Н., Логинова Е. Ю., Коротаева Т. В., Баткаев Э. А. Поражение костно-суставного аппарата у больных псориазом по данным скринингового опросника PEST (Psoriasis Epydemiology Screening Tool) и ревматологического клинико-инструментального обследования. Научно-практическая ревматология. 2014; 52 (6): 636–642.Deane K. D., El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat. Rev. Rheumatol. — 2014. — 10, 212–228.Deane K. D., El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat. Rev. Rheumatol. — 2014. — 10, 212–228.Haroon, M., Gallagher, P. & FitzGerald, O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 74, 1045–1050 (2015).Haroon, M., Gallagher, P. & FitzGerald, O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 74, 1045–1050 (2015).Gladman, D. D. Early psoriatic arthritis. Rheum. Dis. Clin. North Am. 38, 373–386 (2012).Gladman, D. D. Early psoriatic arthritis. Rheum. Dis. Clin. North Am. 38, 373–386 (2012).Ritchlin C. T., Colbert R. A. & Gladman D. D. Psoriatic arthritis. N. Engl. J. Med. 376, 957–970 (2017).Ritchlin C. T., Colbert R. A. & Gladman D. D. Psoriatic arthritis. N. Engl. J. Med. 376, 957–970 (2017).Villani A. P. et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and metaanalysis. J. Am. Acad. Dermatol. 73, 242–248 (2015).Villani A. P. et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and metaanalysis. J. Am. Acad. Dermatol. 73, 242–248 (2015).Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. Arthritis and rheumatology. — 2016. — Vol. 68. — 1060–1071.Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. Arthritis and rheumatology. — 2016. — Vol. 68. — 1060–1071.Абдулганиева Д. И., Бакулев А. Л., Белоусова Е. А., Знаменская Л. Ф., Коротаева Т. В., Круглова Л. С., Кохан М. М., Лила А. М., Хайрутдинов В. Р., Халиф И. Л., Хобейш М. М. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генноинженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). — Альманах клинической медицины. 2018. — 46 (5). — С. 426–445.Абдулганиева Д. И., Бакулев А. Л., Белоусова Е. А., Знаменская Л. Ф., Коротаева Т. В., Круглова Л. С., Кохан М. М., Лила А. М., Хайрутдинов В. Р., Халиф И. Л., Хобейш М. М. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генноинженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). — Альманах клинической медицины. 2018. — 46 (5). — С. 426–445.Mease P, van der Heijde D., Landewéet R. et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018; 77: 890–897.Mease P, van der Heijde D., Landewéet R. et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018; 77: 890–897.McInnes I et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017 Nov 1; 56 (11): 1993–2003. DOI: 10.1093/rheumatology/kex301.McInnes I et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017 Nov 1; 56 (11): 1993–2003. DOI: 10.1093/rheumatology/kex301.Mease P et al. Secukinumab, a Human Anti– Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study 2014 Lancet. 2015 Sep 19; 386 (9999): 1137–46.Mease P et al. Secukinumab, a Human Anti– Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study 2014 Lancet. 2015 Sep 19; 386 (9999): 1137–46.Baraliakos X, Coates LC, Gossec L, et al Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to nsaids: primary analysis of the MAXIMISE trial. Annals of the Rheumatic Diseases 2019; 78: 195–196. dx.doi.org/10.1136/annrheumdis-2019-eular.2932.Baraliakos X, Coates LC, Gossec L, et al Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to nsaids: primary analysis of the MAXIMISE trial. Annals of the Rheumatic Diseases 2019; 78: 195–196. dx.doi.org/10.1136/annrheumdis-2019-eular.2932.Gordon K. B. et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N. Engl. J. Med. — 2016. — 375, 345–356.Gordon K. B. et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N. Engl. J. Med. — 2016. — 375, 345–356.Van der Heijde, D. et al. Ixekizumab, an interleukin17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COASTV): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. — 2018. — 392, 2441–2451.Van der Heijde, D. et al. Ixekizumab, an interleukin17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COASTV): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. — 2018. — 392, 2441–2451.Baeten, D. et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann. Rheum. Dis. — 2018. — 77, 1295–1302.Baeten, D. et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann. Rheum. Dis. — 2018. — 77, 1295–1302.

The authors declare that there are no conflicts of interest present.